
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AUM601
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : AUM Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
AUM Biosciences Identifies Asymchem as the CDMO Partner of Choice for their Novel TRK inhibitor
Details : Under the terms of the agreement, AUM and Asymchem agree to collaborate on the process development, and the clinical and commercial production, of AUM 601, which is a highly selective oral small-molecule inhibitor of the tropomyosin receptor kinase for t...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 11, 2022
Lead Product(s) : AUM601
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : AUM Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : LaNova Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Asymchem and LaNova Medicines Enter into Partnership Agreement, Expanding Biological Capabilities
Details : The partnership between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 16, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : LaNova Medicines
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Yeast Recombinant Lipase,Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the terms of the agreement, Asymchem will implement fermentation, verify protein expression and ultimately fine-tune the technology suitable for production of MS1819.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Undisclosed
November 10, 2020
Lead Product(s) : Yeast Recombinant Lipase,Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Partnership
